AstraZeneca PLC, the second-largest drugmaker in the U.K., said on Wednesday that it would pay up to $2.1 billion in cash and debt to buy the rights to respiratory drugs owned by Spanish group Almirall.
As part of the deal, AstraZeneca will pay an initial $875 million for the respiratory drugs and an additional $1.22 billion if the drugs meet certain development and sales goals. The deal is subject to regulatory approval and is expected to be completed by the end of 2014.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
